anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A similar hormone-driven cancer akin to breast cancers is prostate cancer. These tumors are driven by androgen receptor signaling, and CDK4/6 has also been found to be a bona fide target pre-clinically for advanced prostate cancer cell models. Moreover, CDK4/6 inhibition can act as a radiation sensitizer through its effects on the DNA damage response and interactions with cell cycle pathway proteins. For example, it has been found that expression of DNA repair proteins can be regulated by E2F, a transcription factor necessary for the G1 to S phase transition. Also, cyclin D1 has been found to exert a direct role in DNA repair. Lastly, CDK4/6 inhibition has been found to modulate the DNA damage response. These data support the use of CDK4/6 inhibitors as a modulator of DNA damage to enhance sensitivity to radiation.

Given the role of CDK4/6 in tumor resistance to endocrine therapy, in activation of the DNA damage response, and in promoting radiation resistance, we hypothesize that the targeting of CDK4/6 with abemaciclib will enhance the cytotoxicity in combination with blockade of the androgen receptor pathway. Therefore, we propose a pilot phase II investigator initiated trial in patients with high-risk prostate cancer testing the tolerability and toxicity of abemaciclib in combination with ADT.

Patients will receive ADT for 2 years and will start 3 months before radiation therapy. Abemaciclib will start with initiation of ADT and pause 2 weeks prior to start of radiation therapy. Abemaciclib will resume with the first ADT administration post-radiation, which is about 1 month post radiation therapy. Abemaciclib and ADT will continue for a total ADT period of 24 months. Patients will receive study treatment until development of toxicity or disease progression on treatment or any reasons of withdrawal or a maximum of 24 months of therapy with ADT. Patients are seen every 4 weeks with laboratory evaluation. For toxicity or adverse events, patients will undergo labs, physical examination and grades of toxicities will be determined using NCI CTCAE version 4.03.
Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution is an eyedrop. The usual dose is one drop in the morning and one drop in the evening. Your doctor will tell you if just one or both eyes are to be treated. If you are using Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution with another eyedrop, the eyedrops should be used at least 10 minutes apart. It is very important to use your medication exactly as directed by your doctor. If you stop using your medicine, contact your doctor immediately. Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution contains a preservative called benzalkonium chloride. This preservative may be absorbed by soft contact lenses. Contact lenses should be removed before using Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution. The lenses can be placed back into your eyes 15 minutes after using the eyedrops. Do not allow the tip of the bottle to touch the eye or areas around the eye. The bottle may become contaminated with bacteria. This can cause eye infections leading to serious damage to the eye, even loss of vision. Keep the tip of the bottle away from contact with any surface to avoid contamination.
Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive amifampridine in Period I and then crossed over to receive placebo in Period II. Each randomized treatment period is 7 days in duration and is separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
The anaesthesiologist uses ultrasound to identify the nervous plane in-between the external and transverse abdominal muscles. A dose of 20 cc 3,75 mg/ml of Ropivacain is administered on each side of the abdominal wall in the midaxillary line, just in between the crista and costal margin.
A device which is used in the vagina to deliver spermicidal surfactants. This device can be inserted by the user, and does not require insertion by a physician as, for example, in the case of intrauterine contraceptive devices. By virtue of its unique construction and shape, the device herein is foldable for easy insertion. Once in position at the cervical os, the device opens to "cap" the os and remain in position, even during intercourse, so that access of the spermicidal surfactant source to the cervical os is not interrupted. The device is designed to remain comfortably in the vagina during the time between menstrual periods to provide desirable, prolonged release of a spermicidal surfactant, and its construction and shape facilitate retention therein while minimizing awareness and discomfort. An effective between-period contraceptive device is thereby provided.
OBJECTIVE: Whether socioeconomic status (SES) is associated with health outcomes in patients with acute limb ischemia (ALI) is largely unknown. We aimed to determine whether SES is associated with worse presentations and outcomes for patients with ALI.
METHODS: We performed a retrospective medical record review of patients who presented with ALI between April 2016 and October 2020 at a single tertiary care center. SES was quantified using individual variables (median household income, level of education, and employment) and a composite endpoint, the neighborhood deprivation index (NDI). The NDI is a standardized and reproducible index that uses census tract data (higher number indicates lower SES status). The NDI summarizes 8 domains of socioeconomic deprivation. ALI severity was categorized using the Rutherford classification. The association between SES and the severity of ALI at presentation and between SES and other health outcomes were analyzed using bivariate analysis of variance, independent t test, and multivariate logistic regression.
RESULTS: During the study period, 278 patients were treated for ALI, of whom 211 had complete SES data available. The mean age was 64 years, 55% were men, and 57% were White. The Rutherford classification of disease severity was grade 1, 2a, 2b, and 3 for 6%, 54%, 32%, and 8% of patients, respectively. Patients with a low SES status per the NDI were more likely to have a history of peripheral arterial disease and chronic kidney disease at presentation. The ALI etiology (thrombotic vs embolic) was not associated with SES. No significant differences were seen between SES and the severity of ALI at presentation (p = 0.96) or the treatment modality (p = 0.80). No associations between SES and 30-day or 1-year mortality were observed (mean NDI, 0.15 vs 0.26, p = 0.58, and 0.20 vs 0.26, p = 0.71, respectively) or between SES and 30-day or 1-year limb loss (mean NDI, 0.06 vs 0.30, p = 0.18, and 0.1 vs 0.32, p = 0.17, respectively). Lower SES (higher NDI) was associated with increased 30-day readmission (mean NDI, 0.49 vs 0.15, p = 0.021). However, this association was not significant on multivariate analysis (odds ratio 1.4, 95% CI 0.9-2.1, p = 0.06).
CONCLUSIONS: SES was not associated with the severity of ALI at patient presentation. Although SES was associated with the presence of peripheral arterial disease and chronic kidney disease at presentation, SES was not a predictor of short-term or 1-year limb loss and mortality. Overall, ALI presentation and treatment outcomes were independent of SES.
Jumper's knee is an overuse injury of the tendon that alters the knee due to repeated stress of activities. Symptoms include pain in the front of the knee. The tears are typically caused by accumulated stress on the patellar or quadriceps tendon. As the name implies, the condition is common in athletes from jumping sports, where there is a high demand for the speed and power of leg extensors. These sports often lead to high eccentric quadriceps loadings, such as volleyball, track (long and high jump), basketball, long-distance running, and skiing. The prevalence of jumper knee is not well examined so far. For non-elite adult athletes the prevalence varies between 14.4% and 2.5% for different sports.Only 2.4% of adolescent professional soccer players sustain PT. However, knee pain, focal tenderness or even acute episodes of PT have a major impact on each player's development, time off the pitch, and career.Bioptron was used for treatment of arthritis, neck\&back pain by stimulating blood circulation, reducing inflammation and relieving muscle spasm. There are some studies that have discussed the extent of the effect of the Bioptron Light Therapy on musculoskeletal disorders such as; rotator cuff tendinitis, tennis elbow, carpal tunnel syndrome, acute patellar tendinopathy and acute ankle sprain. There is a lack of the evidence of the clinical guidelines of patellar tendinitis. Up to our knowledge, there is no clear recommendation about efficiency of different colors of Bioptron light therapy on jumper knee. So; this study will be conducted to determine efficiency of yellow and green colors of polychromatic non-coherent light. Sixty subjects will participate in this study and will be divided randomly into three equal groups.Group A (Study group): Will receive green filter of bioptron light therapy and conventional treatment for jumper knee,group B (Study group): Will receive yellow filter of bioptron light therapy and conventional treatment for jumper knee and group C (Control group): Will receive conventional treatment (ice application+ exercise program) for jumper knee.
This study aimed to evaluate the effects of ursolic acid (UA) on Angiotensin II (Ang II)-treated neonatal rat cardiac fibroblasts (rCFs) as an in vitro model of cardiac fibrosis. The rCFs were isolated from two-day-old neonatal rats. An in vitro model of cardiac fibrosis was established using 500 nm Ang II treatment for 48 h. The cells were then treated with 5 and 10 μM of UA for 24 and 48 h. Masson's trichrome staining, hydroxyproline content assay, scratch assay, apoptosis assay, measurements of superoxide dismutase (SOD) and malondialdehyde (MDA) levels, real-time PCR, immunocytology and western blotting, were employed to assess the impact of UA. Ang II induced fibrosis in rCFs, as evidenced by the examination of various fibrotic markers. Upon treatment with 5 and 10 μM of UA, the amount of fibrosis in Ang II-treated rCFs was significantly decreased, so that the hydroxyproline concentration was reduced to 0.3 and 0.7 times, respectively. The RNA expression of the Col1a1, Col3a1, Tgfb1, Acta2 and Mmp2 genes had a decrease as well as Nrf2 and HO-1 had an increase after UA treatment. UA could lessen the harmful effects of cardiac fibrosis in a dose- and time-dependent manner, due to its antiapoptotic, antioxidant and cardioprotective properties. This suggests the potential of UA for treatment of cardiac fibrosis.
Risk Summary

There is no information available on the presence of SIGNIFOR LAR in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Studies show that pasireotide administered subcutaneously passes into the milk of lactating rats; however, due to species-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SIGNIFOR LAR, and any potential adverse effects on the breastfed child from SIGNIFOR LAR or from the underlying maternal condition.

Data

Available data in animals have shown excretion of pasireotide in milk. After a single 1 mg/kg [14C]-pasireotide subcutaneous dose to lactating rats, the transfer of radioactivity into milk was observed. The overall milk:plasma (M/P) exposure ratio of total radioactivity was 0.28, based on AUC0-∞ values.
Group A will consist of preterm infants born \< 37 weeks gestational age. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
Approximately 16\~20 Chinese subjects will be enrolled. Eligible subjects are HER2 positive, metastatic breast cancer who has received standard anti-HER2 directed therapy in the metastatic setting in Chinese patients. Subjects should have received treatment with at least one, and no more than four lines of therapy overall in the metastatic setting.

Eligible subjects will receive margetuximab plus chemotherapy. The dosage and administering of margetuximab is 15 mg/kg IV Q3W. Investigators selected one of three backbone chemotherapy regimens given at standard doses: capecitabine, vinorelbine or gemcitabine. Subject will receive the treatment until disease progression, unacceptable toxicity, withdrawal of consent, initiation of subsequent anti-tumor treatment therapy, or death (whichever occurs first).
The present invention relates to pharmaceutical compositions, dried powders and methods of making the same. The present invention therefore relates to pharmaceutical compositions comprising levosimendan, wherein levosimendan is present in solubilized form. The formulations have therapeutically and commercially useful levosimendan concentrations. The solutions of the invention have an enhanced capacity at physiological pH (pH 7.4) and are particularly suitable for use as infusion solutions or injection solutions or infusion concentrates. The composition according to the invention can also be spray-dried or lyophilized to obtain a very stable dried powder, and the powder forms the original solution after reconstitution in water or an aqueous solvent. Levosimendan or (-) - [ [4- (1,4,5, 6-tetrahydro-4-methyl-6-oxo-3-pyridazin-yl) phenyl ] hydrazone ] malononitrile is useful for the treatment of congestive heart failure.
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by fluctuating muscle weakness and symptoms that interfere with activities of daily living and negatively impacts quality of life. MG symptoms are currently assessed in person through a careful history and physical exam by a neuromuscular disease expert. Such in-clinic assessments are time-consuming, subjective, only provide a snapshot of a patient's disease and do not adequately reflect the spectrum of fluctuating weakness and symptoms. In 2019, NIH funded a rare disease clinical research consortium called MGNet. The consortium is focused on improved characterization of clinical phenotypes, discovery of biomarkers, and advancing clinical trial readiness for MG, which would enhance the development of more effective and personalized treatments. In this Fast Track SBIR project, BioSensics will collaborate with Massachusetts General Hospital - one of the key Consortium sites for MGNet - to develop and validate a wearable sensor solution (MGWear) for continuous remote monitoring of motor symptoms and function in MG patients and also a secure mobile application (MG app) for automatic assessment of speech and facial characteristics. The mobile application will also enable the transfer of data from the wearable device to BioSensics HIPAA-compliant backend cloud called BioDigit Cloud.

The objective of the study is to evaluate the feasibility of using wearable sensor and digital technologies to measure motor and speech function as well as developing metrics to measure ocular and facial expression to monitor disease activity and fluctuating muscle weakness in people with Myasthenia Gravis (MG).To achieve this objective, the investigators will conduct an observational study is to investigate the correlation between outcomes as measured by the PAMSys sensor and digital health technologies with the total score and sub-scores of MG specific outcome measures.

A key application and market for the proposed solution technology is pharmaceutical clinical trials. Wearable sensors and digital technologies like the technology proposed here could allow drug developers to test and iterate faster, providing a valuable new method for evaluating efficacy. Clinically, the proposed solution could be used to predict an individual's response to immunosuppressive drugs and to improve medication titration. Such solutions can enable detecting subtle changes in movement-based and digital biomarkers and provide insight into the phase of clinical disease onset. Additionally, the growing use of telemedicine to expand access and potentially reduce costs of high-quality care will require remote assessment strategies. 20% of states in the US (10 out of 50 states) have no specialized care for MG. Travel time, distance and cost may limit patients' access to expert care, even in states with identified MG specialists. The proposed remote monitoring technologies have potential to lessen barriers to quality care access for MG patients.
AMYNDAS is developing a novel peptidic complement inhibitor AMY-101, based on the third-generation compstatin analogue Cp40. AMY-101 is a selective inhibitor of complement activation in humans and in NHP. It binds to the complement component C3, the central "functional hub" that controls the upstream activation/amplification and downstream effector functions of complement. By binding to C3, AMY-101 inhibits the cleavage of native C3 to its active fragments C3a and C3b. As a consequence, the deposition of C3b, amplification via the alternative pathway and all downstream complement responses are prevented. AMY-101 is being developed to treat complement-mediated diseases, which are largely driven by aberrant C3 activation.

This first-in-human study of the C3-targeting complement inhibitor AMY-101 investigates the safety and PK/PD profile of AMY-101 in healthy male volunteers after Single Ascending Dose (SAD) and Multiple Doses (MD) using subcutaneous (SQ) or intravenous (IV) administration. The study is a prospective, single-center, open-label evaluation in healthy male volunteers.
1387162 Thiopyran derivatives and their preparation ROUSSEL UCLAF 27 July 1972 [27 July 1971] 35235/72 Heading C2C Compounds of the general formula wherein n is 0 or 1 and alkyl represents a C 1-5  alkyl radical, may be obtained by reacting under strongly basic conditions a compound of formula wherein Hal represents a chlorine or bromine atom, with a compound of formula The reaction is preferably effected in the presence of butyl lithium, an alkali metal hydride, an alkali metal amide or an alkali metal alkoxide in a solvent. The compounds of Formula II (wherein n is 0), may also be obtained by reducing a corresponding compound of Formula II (wherein n is 1), e.g. with anhydrous stannous chloride in the presence of acetyl chloride or with titanium trichloride. Compounds of the formula are obtained by either reducing and desulphurizing a compound of Formula II (wherein n is 1), or desulphurizing a compound of Formula II (wherein n is 0). Both the desulphurization and simultaneous reduction and desulphurization processes may be effected by using Raney nickel. The starting materials of Formula III may be obtained by the method described in Specification 1,387,161. The products of Formula II possess insecticidal properties and may be formulated together with other conventional additives.
The invention relates to anti-duck virus hepatitis (DVH) subprostrate sophora polysaccharide and a molecular modifier thereof, belonging to the technical field of preparation of Chinese veterinary medicaments. Different alcohol precipitation fractions of the subprostrate sophora polysaccharide are extracted. An anti-duck virus hepatitis (DVH) active site is screened by means of repeated clinical tests. The following optimal conditions for modifying a subprostrate sophora polysaccharide active site by means of chlorosulfonic acid-pyridine sulfation are determined by using an orthogonal method: the reaction temperature is 95 DEG C, the reaction time is 2 hours, and the ratio of chlorosulfonic acid to pyridine is 1:5. According to infrared spectroscopic analysis, an obtained product is subprostrate sophora polysaccharide sulfate, the saccharide content is up to 83.77 percent, the sulfate content is up to 39.33 percent, and the yield is up to 117.33 percent. The subprostrate sophora polysaccharide sulfate is remarkably superior to the subprostrate sophora polysaccharide in resistance of DHV-1 infection of duck fetal liver cells and curative effect on DVH. The obtained anti-DVH subprostrate sophora polysaccharide active site sulfate is high in saccharide and phosphate contents and yield, and has a good curative effect on DVH.
Nanoconjugates include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold. At least one imaging moiety and at least one targeting module is conjugated to the polymalicacid based molecular scaffold. Methods of synthesizing the nanoconjugate involve providing a polymalic acid having a plurality of pendant carboxyi groups. The method reacts a compound containing sulfhydryl groups and amino acid groups through the pendant carboxyi groups to add sulfhydryl groups to the polymalic acid to form an activated polymalic acid. The method reacts at least one imaging moiety containing a sulfhydryl binding group to the activated polymalic acid to form a preconjugate. The method may involve administering to the subject a nanoconjugate that includes a polymalic acid-based molecular scaffold, at least one imaging moiety, and at least one targeting module.
Atropine Sulfate Injection, USP, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. It may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery.

The antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine concomitantly with morphine may be indicated.

Atropine relaxes the upper GI tract and colon during hypotonic radiography.

In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. It is also used as an antidote for mushroom poisoning due to muscarine in certain species such as Amanita muscaria.
Subjects will receive usual care provided at the DM clinic. All subjects will receive a self-help cessation manual and take the exhaled carbon monoxide test. Counselor will give follow-up calls to the patients to assess their smoking status and other health-related lifestyle practices. Three consecutive (3-, 6- and 12-month) follow ups will be conducted with all participants. The total counseling process will take about 20 minutes.
Patients with persistent hemodynamic instability (systolic blood pressure (SBP) \<90 mmHg after the transfusion of 4 packed red blood cell (PRBC) units in the emergency department) were taken urgently to the angiography suite for pelvic angiography. These patients had to tolerate transfer to the suite. Patients receiving primarily angioembolization therapy were defined as the ANGIO group.